The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Christophe Le Tourneau
No relevant relationships to disclose
Yungan Tao
No relevant relationships to disclose
Jean-Pierre Delord
Consultant or Advisory Role - Debiopharm Group
Silvano Brienza
Employment or Leadership Position - Debiopharm Group
Gregoire Vuagniaux
Employment or Leadership Position - Debiopharm Group
Marie-Paule Sablin
No relevant relationships to disclose
Claudio Zanna
Employment or Leadership Position - Debiopharm Group
Jean Bourhis
Consultant or Advisory Role - Debiopharm Group